---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036279"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:40:53.934739+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Insmed Q2 2024 revenue $90.3M (+17% YoY); net loss $300.6M; guides FY $340-360M

## Summary
- ARIKAYCE global revenue $90.3M in Q2 2024, up 17% YoY; U.S. $63.8M, Japan $21.1M, Europe $5.4M.
- Net loss $300.6M ($1.94/sh) vs $244.8M loss ($1.78/sh) in Q2 2023; includes $103.7M non-cash fair value charge.
- Reiterated FY2024 ARIKAYCE revenue guidance $340M-$360M, representing ~15% YoY growth at midpoint.
- Completed public offering of 14.5M shares; net proceeds $713.2M. Redeemed $225M convertible notes due 2025.
- Plan to file NDA for brensocatib in bronchiectasis in Q4 2024; Phase 3 ASPEN met primary endpoint with statistical significance.

## SEC filing metadata
- accession: 0001140361-24-036279
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036124036279/0001140361-24-036279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036124036279/ef20033779_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036279
- JSON: https://secwatch.observer/filing/0001140361-24-036279.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036279.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.